CHEMOTHERAPY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Global chemotherapy market is estimated to be valued at USD 10.87 Bn in 2024 and is expected to exhibit a CAGR of 7.8% during the forecast period (2024-2031). Chemotherapy is a type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. Chemotherapy drugs work by slowing or stopping the growth of cancer cells which grow, divide, and spread more rapidly than normal cells. Chemotherapy is used to treat many types of cancers including breast cancer, lung cancer, colorectal cancer, lymphoma, leukemia, bladder cancer, testicular cancer, ovarian cancer, and others. It is often given intravenously but can also be given by mouth or topically. Chemotherapy is usually given in cycles with each period of treatment followed by a recovery period to allow the body to build healthy new cells. Side effects depend on the specific drugs used, dosage, and the patient but can include fatigue, loss of appetite, nausea, vomiting, hair loss, mouth sores, and lowered immunity.

Market Dynamics:

The rising prevalence of various types of cancers and the growing geriatric population, which is increasingly susceptible to developing cancer, are significant factors expected to drive the growth of the chemotherapy market in the coming years. Additionally, the increasing demand for targeted drug therapies and personalized medicine, along with technological advancements in drug delivery systems and a strong pipeline of novel chemotherapy agents in clinical development, will further enhance market expansion. However, the toxicity and side effects associated with chemotherapy drugs, risk of drug resistance, high costs of cancer drugs, and lack of healthcare infrastructure and awareness in developing countries are likely to restrain the market to a certain extent over the forecast period. Development of innovative drug delivery systems to reduce toxicity and improve efficacy and targeted delivery of anti-cancer drugs hold promising opportunities for players in this market.

Key Features of the Study:

• This report provides in-depth analysis of the global chemotherapy market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global chemotherapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc., Novartis AG, GSK plc., Sanofi, Amgen Inc., Gilead Sciences, Inc., Boehringer Ingelheim International GmbH., AbbVie Inc., Merck & Co., Inc., Eureka Therapeutics, Inc., Verismo Therapeutics, Inc., Bayer AG, and Autolus Therapeutics
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global chemotherapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chemotherapy market

Market Segmentation

• By Drugs Insights (Revenue, USD Bn, 2019 - 2031)
• • Alkylating agents
  • Antimetabolites
  • Anti-tumor antibiotics
  • Others
• By Cancer Type Insights (Revenue, USD Bn, 2019 - 2031)
• • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Blood Cancer
  • Liver Cancer
  • Others
• By Route of Administration  Insights (Revenue, USD Bn, 2019 - 2031)
• • Oral
  • Parenteral
  • Others
• By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
• • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
• • Bristol-Myers Squibb Company
  • AstraZeneca
  • Pfizer Inc.
  • Novartis AG
  • GSK plc.
  • Sanofi
  • Amgen Inc.
  • Gilead Sciences, Inc.
  • Boehringer Ingelheim International GmbH.
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Eureka Therapeutics, Inc.
  • Verismo Therapeutics, Inc.
  • Bayer AG
  • Autolus Therapeutics